Showing 1 posts of 1 posts found.
A muscular drug developed by Novartis (NYSE: NVS), in partnership with MorphoSys (ETR: MOR), failed to meet its primary endpoint …
PinPoint signs laboratory partnership to expand access to AI cancer risk test
NHS expands community ear and hearing pathway across 10 ICBs
London secures major investment to accelerate healthcare innovation
People with severe mental illness more likely to die early from cardiovascular disease, report finds
Yourgene wins Australian approval for chemotherapy toxicity screening assay